Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY, a HUMIRA® biosimilar, available to patients

YUSIMRY (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) — Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs or Mark Cuban … Read more

How medical recoding may limit options for breast reconstruction for cancer patients

The federal government is reconsidering a decision that breast cancer patients, plastic surgeons and members of Congress have protested would limit women’s options for reconstructive surgery. On June 1, the Centers for Medicare & Medicaid Services plans to review how doctors are paid for a type of breast reconstruction known as a DIEP flap, in … Read more

More depressed patients than previously estimated may have increased activation of their immune systems

Credit: Unsplash/CC0 public domain New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has used an assessment of gene expression involved in the immune response to show that there may be more major depressive disorder (MDD) patients with activated immune systems than research has previously estimated. By identifying the … Read more

FDA Proposes New Easy-to-Read Drug Guide for Patients, Drug Information for Patients

For immediate release: May 30, 2023 Statement from: Robert M. Califf, MD, MACC Food and Drug Commissioner – Food and Drug Administration Providing people with accurate and timely information to help them take their prescribed medications safely and effectively is a top priority for the United States Food and Drug Administration. Evidence suggests that easier-to-read … Read more

Single Dose Of Psilocybin Causes Long-Term Remission Of Depression In Over 50% Of Cancer Patients | Psychedelic spotlight

Great news for those researching new treatments for depression in cancer patients! Positive long-term follow-up data has just been released from Sunstone Therapies investigator-initiated Phase 2 study evaluating synthetic psilocybin COMPASS Pathways, with some rather promising results. Administration of a single 25 mg dose of psilocybin combined with psychological support resulted in 57% of patients … Read more

What Lawmakers Did and Didn’t Do for Healthcare Professionals, Patients – Oklahoma Watch

House and Senate Republicans moved quickly to advance a bill banning some health care for transgender youth, but measures that clarify or carve out exceptions to the state’s near-total abortion ban have stalled at the moment. start of the legislative process. Here’s a look at what state lawmakers did and didn’t do on health care … Read more

Advance insurance clearances hurt patients

An oft-repeated phrase that dates back to the 4th century BC is that physicians shouldn’t do harm first when treating patients. Nowadays, insurance companies that report to their investors and not to Hippocrates often prioritize monetary gains over patient care. Prior authorization is one way that insurance companies protect their profits and sometimes cause harm … Read more

The nurse is accused of killing 2 patients through a lethal dose of insulin

Heather Pressdee, 40, is accused of giving lethal doses of insulin to three men at Quality Life Services in Chicora, Pennsylvania Two of the men died from the overdose and all three were under Pressdee’s care at the time of the incidents, according to prosecutors. Pressdee says one of the men told her to ‘kill … Read more

Pennsylvania nurse accused of killing 2 patients, injuring another with insulin injections

A Pennsylvania nurse is accused of giving lethal doses of insulin to two patients, the state attorney general said. Heather Irene Pressdee, 40, of Natrona Heights, allegedly gave patients “insulin overdoses” as a registered nurse at Quality Life Services, a skilled nursing facility in Chicora, the Pennsylvania attorney general’s office said in a statement. press. … Read more

Dupilumab is the first investigational biologic to significantly improve lung function in COPD patients

Dupilumab (Dupixent; Sanofi) is the first and only investigational biologic to significantly improve lung function at 12 and 52 weeks and significantly reduce severe acute exacerbations compared with placebo in adults with chronic obstructive pulmonary disease (COPD), according to the authors. presented a positive Phase 3 best outcome at the 2023 American Thoracic Society (ATS) … Read more